Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | BMP1 | P13497 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699717 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDESR1BMP1 | |
| SCHEMBL4702684 | 0.94 | BMP1 (0.48) | ALDH1A1MAPTHPGDESR1BMP1 | |
| SCHEMBL4702685 | 0.94 | BMP1 (0.48) | ALDH1A1MAPTHPGDESR1BMP1 | |
| SCHEMBL4704851 | 0.92 | ESR1 (0.56) | ALDH1A1MAPTHPGDESR1KEAP1 | |
| SCHEMBL4704854 | 0.92 | ESR1 (0.56) | ALDH1A1MAPTHPGDESR1KEAP1 | |
| SCHEMBL4702500 | 0.89 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDESR1HTT | |
| SCHEMBL4702502 | 0.89 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDESR1HTT | |
| SCHEMBL5531936 | 0.85 | MAPT (0.56) | ALDH1A1MAPTHPGDKEAP1HTT | |
| SCHEMBL5531935 | 0.85 | MAPT (0.56) | ALDH1A1MAPTHPGDKEAP1HTT | |
| SCHEMBL1883915 | 0.83 | MAPT (0.52) | ALDH1A1MAPTHPGDHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648896-B1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INT (ES) | 2008-02-13 | — | — | EP | disclosed |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | FERRER INTERNACIONAL S.A. (ES) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | GABRB1, GABRA1, GABRB2 | ALDH1A1 113/4885MAPT 2772/4885HPGD 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.